BRISTOL-MYERS CREATING NEW DIVISION TO MARKET GENERIC DRUGS, the company announced in a recent press release. The new Evansville, Indiana-based unit, Bristol-Myers Pharmaceutical Division, will market the U.S. Pharmaceutical and Nutritional Group's current line of generic pharmaceuticals and have the additional responsibility for contract sales of these products to both the federal government and health maintenance organizations. "The formation of this new division will enable Bristol-Myers U.S. Pharamceutical and Nutritional Group (USPNG) to be more competitive in the changing health care environment," the release states. "In particular, the new division will position USPNG to take advantage of opportunities in two areas of growing importance -- the expanding generic pharmaceutical market, and the move towards centralized drug selection by large buying influences, such as HMOs." The announcement makes Bristol-Myers the third major U.S. brandname company within the past few months to establish a separate marketing arm for off-parent pharmaceuticals, giving the generic business a higher profile within the company. As part of a reorganization move last summer, Squibb announced the creation of a new division, SquibbMark, to market its OTC and generic Rx products via a 70-rep sales force. Recently, Warner-Lambert indicated its intention to remove its generic business from Parke-Davis and place it into a separate division, Warner-Chilcott, by the end of the year. The release notes that the new Bristol-Myers unit will sell its products under the Apothecon label, which was formerly used by Bristol Labs to sell generic antibiotics to large chain drug stores. Among the antibiotics to be marketed by the Pharmaceutical Division are Polycillin, Polymox, Prostaphlin, Staphcillin, Tegopen, Dynapen, Betapen, Kantrex, Nafcil and Precef. While the new division's initial product line is limited to antibiotics, the company said it anticipates selling non-antibiotic, off-patent drugs in the future.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.
Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.
The International Council for Harmonisation has developed a holistic approach for the assessment and control of leachable impurities, supporting drug product development, registration and ongoing quality management throughout the product lifecycle.
